Influenza B/Yamagata Update

Lisa Groshkopf, MD, MPH

Advisory Committee on Immunization Practices
February 28, 2024
Influenza B/Yamagata and 2024-25 Influenza Vaccines

• Quadrivalent influenza vaccines introduced in 2013-14 to provide broader coverage of influenza B viruses.
  – Quadrivalents contain one influenza B virus from each lineage (Victoria and Yamagata).
  – Transition from trivalents to quadrivalents complete by the 2021-22 influenza season.
• No confirmed influenza B/Yamagata viruses in global surveillance since March 2020.
• WHO and the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) have recommended excluding B/Yamagata from influenza vaccines.
• WHO has made recommendations for Northern Hemisphere 2024-25 vaccines.
  – Decisions regarding composition are made by individual national regulatory authorities.
• VRBPAC to discuss composition of 2024-25 U.S. influenza vaccines on March 5, 2024.

Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season (who.int)
Vaccines and Related Biological Products Advisory Committee October 5, 2023 Meeting Announcement - 10/05/2023 | FDA
Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season (who.int)
Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement - 03/05/2024 | FDA